Merck's Keytruda Survives 'Conflicted' Adcom Vote For Bladder Cancer Indication

 
• By Derrick Gingery

Many Oncologic Drugs Advisory Committee members struggled to decide whether the data showed a clinically meaningful benefit in the proposed bladder cancer indication.

FDA Advisory Committee Feature image
Those against a favorable benefit-risk assessment said the KEYNOTE-057 trial data was not adequate for Keytruda in the proposed high-risk bladder cancer indication.

More from US FDA Performance Tracker

More from Regulatory Trackers